PDCD1 and neoplasm: Meanwhile, high expression of PLCG2 might promote the expression of PD-L1 and PD-1, thus hampering the killing effect of T lymphocytes on tumor cells, diminishing the efficacy of immunotherapy, and facilitating immune escape.